Research & development

Slides:



Advertisements
Similar presentations
Consultative expert working group - proposals Barcelona
Advertisements

Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
COMPETITION POLICY AND ECONOMIC DEVELOPMENT PRESENTATION AT CUTS-ARC CAPACITY BUILDING WORKSHOP, LUSAKA 7 TH MARCH, 2011 BY SAJEEV NAIR, COMPETITION POLICY.
Pharma/BIOTECH industry overview
1 New Delhi 12 May 2011 by D G Shah Secretary General Indian Pharmaceutical Alliance Pharmaceutical Innovation Issues & Challenges RIS and Indian Council.
An Overview of the Canadian Pharmaceutical Industry
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
Biotechnology The Israeli Case Definition Using living organisms, cells or biological agents, to produce goods and services. Modern biotechnology arose.
Ownership and distribution Ethical issues in patenting Pr Samia Hurst Institute for Biomedical Ethics University of Geneva Medical School.
The Pharmaceutical Industry. Industry introduction Opportunity How to get into this industry ?
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Michelle Boudreau, Vice President, Private Markets, March 11, 2015 Presentation to CADA.
Did you know...  That one in every six people on this globe suffers from a disease of poverty?  That ten million people die each year from diseases.
Pharmaceutical Industry Analysis Nature of the industry: Highly defensive and 15% of U.S. population aged over 60→Highly mature. Main forces are the suppliers,
1 Global New Employee Orientation Workshop Welcome.
Pharmacology II. The Business of Sick.
Yank D. Coble, MD, MACP, MACE Director and Distinguished Professor Center for Global Health and Medical Diplomacy University of North Florida, Jacksonville,
Stages of drug development
I MPACT OF P HARMACOGENOMICS ON THE P HARMACEUTICAL I NDUSTRY Viktoriya Buchko American Institute of Chemical Engineers August 6, 2008.
STRATEGIC MANAGEMENT 1 Irina Raynaud Pierre Jean Tessier Nicolas Cabrit Clément Tumoine.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
Pfizer Incorporated. Beginning Founded by cousins Charles Pfizer and Charles Erhart in 1849 Goal Discover and develop new and better ways to prevent and.
S TRATEGY IN THE TWENTY - FIRST CENTURY PHARMACEUTICAL INDUSTRY : M ERCK & C O. AND P FIZER INC. MGMT 495 Summer 2011: Kelly Bossolt Marta Kovorotna Sarah.
Todd Hamilton District Sales Manager. Innovation  On average it takes scientists, physicians, engineers, and other researchers between 10 and 15 years.
Intellectual Property and Innovation … The Virtuous Cycle Khaled Mansour Area Managing Director, Janssen, Middle East, West Asia and Africa.
1 Intellectual Property in the Innovative Pharmaceutical Industry *** June 12, 2006 Gregg C. Benson Assistant General Counsel – Intellectual Property 1.
TRIPS and Public Health: Thailand’s Compulsory Licenses over Patented Drugs for Chronic Diseases December 2, 2013 By Sakda Thanitcul.
Joan Holloway Vice President, Global Health Initiatives Multidisciplinary Care Team Delivery of Integrated HIV Services.
CFO Track John Lawson & Pierre Bourassa Traditional Drug Development process.
Hitetrapib – Eliminating Heart Disease Gillian Brazier Development Head, Cardiovascular Medicine.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
PUTTING THE PATIENT AT THE CENTER OF HEALTHCARE RESEARCH Towards a more inclusive model.
ERM and the Pharmaceutical Industry. Risk  An innate part of every aspect of life, and the business environment is of no exception  Severity, both in.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
By Georgi Boyanov BUS 449a: Change Management.  Statistics  History  Medicinal recipes  Vaccines  Innovation  Mergers & Acquisitions.
 Overview of pharma industry  Know associate industry in pharma  Environmental forces  Stakeholders.
“Supporting the Industry through Communication” The pharmaceutical industry is committed to the research, development, quality manufacturing and logistics.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
BioMedical Cluster New opportunities for innovators and investors with Bio-Medical Cluster of Skolkovo Foundation Innovation in Medical Technologies Conference,
Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.
Inventions Research & Development (R&D) in Pharmaceuticals DISCOVERY Enzymes, receptors, & genetics, DEVELOPMENT Safety, quality and efficacy tests PRODUCTION.
Innovation and the Pharmaceutical Research and Development Industry January 2002 MSD South Africa.
PHARMA HELPLINE SOCIETY we care,we assist, we help Announces on line courses for the overall development of pharmacy professionals and students. These.
Success Stories of Globalization in Korean Pharma
Taxonomy of Strategies
Group drug purchasing platform in a cheaper way for Africa
Providing Hope to Patients and their Families Around the World!
Clinical Trials Medical Interventions
Our Company Ashman group is a new generation for Ashman Global in field of pharmaceutics and Nutraceuticals Our divisions embrace research and science.
Better Lives. Together. The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Gestora brasileiro focada exclusivamente na área da saúde.
Fiona Caplan-Dean Pharmacy Services Development Manager UK
Prescription for Pharmaceutical Reform: Healing an Ailing System
Non For Profit Model for Rare Disease Therapy Development
Clinical Trials.
AIKTC - School of Pharmacy
An Industry Perspective Nicole Denjoy COCIR Secretary General
Innovation & the Pharmaceutical Research & Development Industry
IP Provisions in Bilateral & Regional Trade Agreements and Public Health ICTSD/QUNO Dinner Discussion on IPRs in Bilateral & Regional Trade Agreements.
A science-led global healthcare company with a special purpose
Drug Pricing, Innovation, and the Cycle of Greed
LPRI – R&D Pharma Madrid, 9th March, 2015.
Pharmaceuticals Industry
Economic Growth & Productivity
An Agency Perspective on Plain Language Summaries of Publications
Global Mental Health and mhGAP Paul Myres, Chair Dolen Cymru
Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.
Presentation transcript:

Research & development There’s never been anything quite like the new Pfizer. Why? Because of you -- the most important element of this new company. Companies like ours don’t get to be where they are without the best people. The people who built Warner-Lambert and the people who built Pfizer are the very best in our fields. United -- and with a redoubled commitment to our shared values -- we can only get even better. Despite all the excitement, mergers are trying times, as people adjust to changes in their professional and personal lives. How we respond to these changes will define our character as a company -- and as individuals. Remember, we are all new to the new Pfizer. We have a company to build, a future to create, and great things to achieve . . . together. Each of us is responsible for welcoming our colleagues with warmth and respect. Each of us is responsible for making the new Pfizer a fulfilling and productive place to work. The new Pfizer is a place of exceptional possibilities for improving the lives of people everywhere, and for creating better lives for ourselves, our families and the communities where we live and work. As we enter the 21st century, more than ever before, life is our life’s work. Welcome to the new Pfizer.

The Phases of Drug Development Pre-Clinical Phase I Clinical Tests Phase II Clinical Tests Phase III Clinical Tests Regulatory Review Regulatory Approval Phase IV Clinical Tests

Average Number of Clinical Trials per NDA

Average Number of Patients in Clinical Trials per NDA

R&D Investment Risks On average: $ 800 million to bring one product to market Only 1 in 5000 molecules developed make it to market as a prescription drug 3 of 10 that do make it to market recoup investment and make a profit.

Drop in Death Rates for Diseases Treated with Pharmaceuticals, 1965-1996

The Good that drugs do… Innovative medicines, by preventing as well as curing disease help make integrated care possible e.g Lipid lowering agents: Reduces cholesterol thereby preventing heart attacks and strokes 183 South Africans die every day from a heart attack or stroke. With Lipid lowering agents: 50% DECREASE in stroke 59% DECREASE in non fatal myocardial infarction

Strong Intellectual Property Improves Public Health Quality drugs reach the market Discourages counterfeit drugs which often pose a public health risk Facilitates Transfer of Advanced Technologies From Developed to Developing Countries Larger Attraction for Skilled Labour

Strong Intellectual Property Fosters Development of Industry Trend towards local R&D vs merely Reproducing medicine R&D and general investment increasing in Pro-IPR countries : E.G. Mexico, Korea and Canada

CORNERSTONES OF INNOVATION Adequate support for biomedical research Strong protection of intellectual property Rigorous, efficient, and transparent regulation of pharmaceuticals Market-based delivery of health care A supportive global business environment

Patent Protection Pharmaceutical patents confer a right to prevent others from producing and selling the specific patented medicine without the permission of the patent holder for a limited time.

life is our life’s work There’s never been anything quite like the new Pfizer. Why? Because of you -- the most important element of this new company. Companies like ours don’t get to be where they are without the best people. The people who built Warner-Lambert and the people who built Pfizer are the very best in our fields. United -- and with a redoubled commitment to our shared values -- we can only get even better. Despite all the excitement, mergers are trying times, as people adjust to changes in their professional and personal lives. How we respond to these changes will define our character as a company -- and as individuals. Remember, we are all new to the new Pfizer. We have a company to build, a future to create, and great things to achieve . . . together. Each of us is responsible for welcoming our colleagues with warmth and respect. Each of us is responsible for making the new Pfizer a fulfilling and productive place to work. The new Pfizer is a place of exceptional possibilities for improving the lives of people everywhere, and for creating better lives for ourselves, our families and the communities where we live and work. As we enter the 21st century, more than ever before, life is our life’s work. Welcome to the new Pfizer.